SCHEMBL6709485

SCHEMBL6709485

CCOC(=O)/C(=C\Nc1ccc(N2CCOCC2)cc1)C(=O)c1cc(CN2CCOCC2)ccc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.47
KDM4E B2RXH2 1/20 0.47
POLB P06746 1/20 0.47
LMNA P02545 2/20 0.46
RAB9A P51151 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
MAPT P10636 4/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
STAT3 P40763 1/20 0.44
NPC1 O15118 4/20 0.43
TP53 P04637 1/20 0.43
DHODH Q02127 1/20 0.42
ALDH1A1 P00352 1/20 0.40
CACNA1B Q00975 1/20 0.40
APBA1 Q02410 1/20 0.40
SAE1 Q9UBE0 1/20 0.40
UBA2 Q9UBT2 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6709489 1.00 NPSR1 (0.47) NPSR1KDM4EPOLBLMNARAB9A
SCHEMBL6710843 0.92 SMN1; SMN2 (0.46) NPSR1KDM4EPOLBLMNARAB9A
SCHEMBL6709470 0.92 SMN1; SMN2 (0.46) NPSR1KDM4EPOLBLMNARAB9A
SCHEMBL6709484 0.91 ALDH1A1 (0.46) NPSR1KDM4EPOLBLMNARAB9A
SCHEMBL6711020 0.91 LMNA (0.48) NPSR1KDM4EPOLBLMNARAB9A
SCHEMBL6709488 0.91 ALDH1A1 (0.46) NPSR1KDM4EPOLBLMNARAB9A
SCHEMBL6711016 0.91 LMNA (0.48) NPSR1KDM4EPOLBLMNARAB9A
SCHEMBL6708280 0.91 HIF1A (0.48) NPSR1KDM4EPOLBLMNARAB9A
SCHEMBL6708277 0.91 HIF1A (0.48) NPSR1KDM4EPOLBLMNARAB9A
SCHEMBL6712562 0.90 MAPK1 (0.47) NPSR1KDM4EPOLBLMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040024209-A1 1-Aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents SCHNUTE MARK E (US) 2004-02-05 US disclosed
US-6653307-B2 Such as N-(4-chlorobenzyl)-6-(4-morpholinylmethyl)-4-oxo-1-phenyl-1,4-dihydro-3-quinolinecarboxamide for treatment of herpes virus; viral DNA polymerase inhibitors PHARMACIA & UPJOHN COMPANY 2003-11-25 US disclosed
EP-1292575-A2 1-ARYL-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-03-19 EP disclosed
US-20020103220-A1 1-Aryl-4oxo-1,4-Dihydro-3-quinolinecarboxamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2002-08-01 US disclosed
WO-2001098275-A2 1-ARYL-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2001-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024209-A1 1-Aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents ZC3HAV1, ZC3HAV1L, IRF3 NPSR1 3951/4885KDM4E 314/4885POLB 697/4885
US-20020103220-A1 1-Aryl-4oxo-1,4-Dihydro-3-quinolinecarboxamides as antiviral agents ZC3HAV1, IRF3, ZC3HAV1L NPSR1 3948/4885KDM4E 178/4885POLB 629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.